Bionic intestinal liver microfluidic cell culture-drug screening integrated chip

Abstract

The invention relates to the technical field of drug experiments, and provides a bionic intestinal liver microfluidic cell culture-drug screening integrated chip which at least comprises a core plate layer, a bottom plate layer and a top plate layer. The core plate layer comprises a bionic intestinal cell region and a bionic hepatocyte region which do not communicate with each other and are separately arranged on two sides of the chip; the bionic intestinal cell region comprises an intestinal cell culture chamber and a vascular endothelial cell culture chamber; the extending directions of the intestinal cell culture chamber and the vascular endothelial cell culture chamber are on the same axis, and the vascular endothelial cell culture chamber is positioned on the outer side of the intestinal cell culture chamber; a bending structure is arranged between the intestinal cell culture chamber and the vascular endothelial cell culture chamber; and the bionic hepatocyte region comprises a plurality of hepatocyte culture chambers which are arranged in a surrounding manner in the circumferential direction, and bionic capillary channels which are arranged between the adjacent hepatocyte culture chambers. According to the scheme provided by the invention, more accurate metabolism data of the organ cells on the medicine can be obtained.

Description

technical field [0001] The present application relates to the technical field of drug experiments, in particular, the present application relates to a bionic intestinal liver microfluidic cell culture-drug screening integrated chip. Background technique [0002] At present, one of the key issues in the fields of drug detection and toxicity screening, disease modeling, disease-related pathophysiology research, and intercellular interactions is how to construct biomimetic tissue structures in vitro. Taking drug screening as an example, it is to accurately simulate the subcellular structure and physiological response of cells in vivo, so as to accurately predict the toxic response of drugs in vivo. The development of new drugs usually includes preclinical drug safety evaluation, such as biochemical analysis, cytology experiments and animal toxicity experiments, and finally applied to the human body. However, most of the candidate new drugs are eliminated in phase III drug clin...

AI Technical Summary

Problems solved by technology

[0003] Moreover, although drug metabolism is completed in the liver, in reality, the absorption and metabolism of drugs is not completed by a single organ

Systemic absorption and metabolism of orally administered drugs mainly occurs in the small intestine and liver, however, in most in vitro studies, drug response studies in these two organs are still lacking for the toxicity of orally administered drugs

Images